Patients' groups welcome NICE decisions on arthritis and multiple sclerosis drugs.
作者信息
Cole Andrew
出版信息
BMJ. 2007 Sep 1;335(7617):416-7. doi: 10.1136/bmj.39318.419410.DB.
Abstract
摘要
相似文献
1
Patients' groups welcome NICE decisions on arthritis and multiple sclerosis drugs.
BMJ. 2007 Sep 1;335(7617):416-7. doi: 10.1136/bmj.39318.419410.DB.
2
FDA OKs two new uses for biologic arthritis drug adalimumab.
Health News. 2006 Jan;12(1):2.
3
Experiences on the use of biological drugs in psoriatic arthritis-associated amyloidosis.
Scand J Rheumatol. 2011 May;40(3):236-8. doi: 10.3109/03009742.2010.530294. Epub 2011 Jan 13.
4
[Effectiveness and safety of biological therapy with adalimumab].
Orv Hetil. 2009 Jun 28;150(26):1215-22. doi: 10.1556/OH.2009.28681.
5
[Autoimmune aspects of treatment with TNF-alpha inhibitors].
Postepy Hig Med Dosw (Online). 2007 Aug 28;61:478-84.
6
Adalimumab-induced neutropenia in a patient with rheumatoid arthritis.
Joint Bone Spine. 2009 May;76(3):312-3. doi: 10.1016/j.jbspin.2008.09.017. Epub 2009 Mar 16.
7
[Proposal for biologic drugs therapy in rheumatoid arthritis].
Reumatizam. 2010;57(1):29-35.
8
[Biologicals in the treatment of rheumatic diseases].
Dtsch Med Wochenschr. 2006 Oct 13;131(41):2279-85. doi: 10.1055/s-2006-951364.
9
[Update in treatment of psoriatic arthritis].
Tunis Med. 2008 Dec;86(12):1036-41.
10
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.
Ann Rheum Dis. 2007 Nov;66 Suppl 3(Suppl 3):iii2-22. doi: 10.1136/ard.2007.081430.
Zotero 插件